Nijhawan Pardeep 4

What Happened

• Pardeep Nijhawan, CEO of Edesa Biotech (EDSA), was granted 3,378 restricted share units (RSUs) on July 2, 2026. The award vested in full upon grant and is reported as an acquisition at $0.00 (total reported value $0).
• This was an equity compensation grant (award), not an open-market purchase or sale. RSU grants are typically part of executive compensation and do not by themselves indicate buying or selling activity in the market.

Key Details

• Transaction date: 2026-07-02; Transaction type: Award/Grant (code A); Price per share reported: $0.00.
• Shares acquired: 3,378 RSUs that vested in full upon grant (total reported consideration $0).
• Post-transaction holdings: Not specified in the filing.
• Footnotes of note:
  • F1: Confirms the RSUs were granted under the issuer’s 2019 Equity Incentive Compensation Plan and vested immediately.
  • F2/F3: Several reported shares are held by entities and a family trust wholly owned or co‑trustee‑managed by the reporting person; Mr. Nijhawan disclaims beneficial ownership of those shares except to the extent of his pecuniary interest.
• Filing timeliness: Reported for the transaction date of 2026-07-02; filing does not indicate a late report.

Context

• RSU awards are a form of compensation and often vest according to company rules; because these vested immediately, the shares became owned by or attributable to the reporting person or related entities on the grant date.
• Such grants are different from open-market buys (which may signal direct bullish conviction) or sales (which may signal liquidity needs); they primarily reflect compensation or retention policies.